InvestSMART

Pilbara Gold Limited (ASX: PGL) - Announcements

Current share price for PGL : $0.485 0.015 (3%)+

ASX company news and announcements for Pilbara Gold Limited (PGL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pilbara Gold Limited (PGL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pilbara Gold Limited (PGL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pilbara Gold Limited (PGL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$113 Preliminary Final Report/Full Year Accounts 31 Aug 2006 10:23AM $2.600 $0.485 fallen by 81.35%
$113 Accelerated Clinical Development of PI-88 post FDA meeting 16 May 2006 8:30AM $3.850 $0.485 fallen by 87.40%
$113 Meets with FDA to progress PI-88 clinical development 27 Mar 2006 10:22AM $3.460 $0.485 fallen by 85.98%
$113 Half Yearly Report & Half Year Accounts 14 Mar 2006 7:07PM $3.080 $0.485 fallen by 84.25%
$113 Discovery of a Novel Class of Compounds 14 Nov 2005 10:40AM $3.170 $0.485 fallen by 84.70%
$113 Preliminary Final Report & Full Year Accounts 5 Sep 2005 10:40AM $2.570 $0.485 fallen by 81.13%
$113 Open Briefing PGL New Phase II Prostate Cancer Trial&Update 15 Aug 2005 10:12AM $2.750 $0.485 fallen by 82.36%
$113 Expand PI-88 Clinical Development to Prostate Cancer 9 Aug 2005 8:30AM $2.990 $0.485 fallen by 83.78%
$113 Offered Ausindustry Commercial Ready Grant 25 Jul 2005 9:50AM $2.730 $0.485 fallen by 82.23%
$113 Response to ASX Query - Share Price 2 Jun 2005 5:47PM $2.100 $0.485 fallen by 76.90%
$113 Response to ASX Query re: Share Price 9 Mar 2005 9:36AM $3.300 $0.485 fallen by 85.30%
$113 Progen Extends PI-88 Melanoma Clinical Program 2 Feb 2005 10:55AM $4.550 $0.485 fallen by 89.34%
$113 Response to ASX Price Query 4 Aug 2004 11:56AM $4.080 $0.485 fallen by 88.11%
$113 US FDA Orphan Drug Status to PI-88 for Melanoma 4 May 2004 9:19AM $3.650 $0.485 fallen by 86.71%
$113 Half Year Results & Encouragement from Avastin's Approval 27 Feb 2004 3:29PM $1.800 $0.485 fallen by 73.06%
$113 Half Yearly Report 27 Feb 2004 3:28PM $1.800 $0.485 fallen by 73.06%
$113 Commences Third PI-88 Phase II Trial 11 Feb 2004 10:37AM $1.590 $0.485 fallen by 69.50%
$113 PI-88 Melanoma Phase II trial commenced 21 Jan 2004 10:58AM $1.660 $0.485 fallen by 70.78%
$113 Bonus Issue of Options - Record Date 28/11/2003 19 Nov 2003 11:26AM $1.400 $0.485 fallen by 65.36%
$113 Bonus Issue of Options - Record Date 28/11/2003 19 Nov 2003 11:26AM $1.400 $0.485 fallen by 65.36%
$113 Disclosure Document: 1 for 8 Bonus Issue of Options 19 Nov 2003 11:26AM $1.400 $0.485 fallen by 65.36%
$113 Sharpens Cancer Focus through Divestment 11 Nov 2003 11:05AM $1.500 $0.485 fallen by 67.67%
$113 New Placement Terms announced 31 Oct 2003 10:57AM $1.520 $0.485 fallen by 68.09%
$113 Secures Institutional Share Placement 18 Sep 2003 11:42AM $1.890 $0.485 fallen by 74.34%
$113 Preliminary Final Report 29 Aug 2003 8:44AM $1.600 $0.485 fallen by 69.69%

551 - 575 of 575 results

Page 23 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.